Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Ancitabine |
EINECS | N/A |
CAS No. | 31698-14-3 | Density | 2.01 g/cm3 |
PSA | 100.59000 | LogP | -1.52610 |
Solubility | N/A | Melting Point |
269-270 °C (dec.)(lit.) |
Formula | C9H11N3O4 | Boiling Point | 422.2 °C at 760 mmHg |
Molecular Weight | 225.204 | Flash Point | 209.1 °C |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
2,2'-O-Cyclocytidine;Cyclocytidine;6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol,2,3,3a,9a-tetrahydro-3-hydroxy-6-imino- (6CI);6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol,2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, stereoisomer (8CI);2,2'-Anhydro(1-b-D-arabinofuranosyl)cytosine;2,2'-Anhydroarabinosylcytosine;2,2'-Anhydrocytidine;2,2'-Cyclocytidine; |
Article Data | 12 |
The CAS register number of Cyclocytidine is 31698-14-3. It also can be called as Ancitabine and the systematic name about this chemical is (2R,3R,3aS,9aR)-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydro-6H-furo[2',3':4,5][1,3]oxazolo[3,2-a]pyrimidin-3-ol. The molecular formula about this chemical is C9H11N3O4 and the molecular weight is 225.20. It belongs to the Active Pharmaceutical Ingredients. Congener of Cyclocytidine that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.
Physical properties about Cyclocytidine are: (1)ACD/BCF (pH 5.5): 1; (2)ACD/BCF (pH 7.4): 1; (3)ACD/KOC (pH 5.5): 1; (4)ACD/KOC (pH 7.4): 1; (5)#H bond acceptors: 7; (6)#H bond donors: 3; (7)#Freely Rotating Bonds: 3; (8)Polar Surface Area: 98.37Å2; (9)Index of Refraction: 1.845; (10)Molar Refractivity: 49.77 cm3; (11)Molar Volume: 111.8 cm3; (12)Polarizability: 19.73x10-24cm3; (13)Surface Tension: 93.9 dyne/cm; (14)Enthalpy of Vaporization: 78.11 kJ/mol; (15)Boiling Point: 422.2 °C at 760 mmHg; (16)Vapour Pressure: 6.77E-09 mmHg at 25°C.
You can still convert the following datas into molecular structure:
(1)SMILES: N=C\2/N=C3/O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N3/C=C/2
(2)InChI: InChI=1/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2/t4-,6-,7+,8-/m1/s1
(3)InChIKey: BBDAGFIXKZCXAH-CCXZUQQUBM
(4)Std. InChI: InChI=1S/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2/t4-,6-,7+,8-/m1/s1
(5)Std. InChIKey: BBDAGFIXKZCXAH-CCXZUQQUSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 1600mg/kg (1600mg/kg) | PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Eksperimental'naya i Klinicheskaya Farmakoterapiya. Vol. 9, Pg. 31, 1980. |
mouse | LD50 | intravenous | 800mg/kg (800mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976. | |
mouse | LD50 | oral | 3400mg/kg (3400mg/kg) | PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Eksperimental'naya i Klinicheskaya Farmakoterapiya. Vol. 9, Pg. 31, 1980. |
mouse | LD50 | subcutaneous | 4050mg/kg (4050mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976. | |
rat | LD50 | intraperitoneal | 1700mg/kg (1700mg/kg) | PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Eksperimental'naya i Klinicheskaya Farmakoterapiya. Vol. 9, Pg. 31, 1980. |
rat | LD50 | intravenous | 820mg/kg (820mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976. | |
rat | LD50 | oral | > 7gm/kg (7000mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976. |